Page last updated: 2024-11-13
naloxone-3-glucuronide
Description
naloxone-3-glucuronide: main metabolite of naloxone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 71311610 |
| MeSH ID | M0508329 |
Synonyms (14)
| Synonym |
|---|
| naloxone-3-glucuronide |
| 22135-79-1 |
| .beta.-d-glucopyranosiduronic acid, (5.alpha.)-4,5-epoxy-14-hydroxy-6-oxo-17-(2-propenyl)morphinan-3-yl |
| naloxone 3-b-d-glucuronide |
| W-201919 |
| unii-86o922u8j0 |
| 86o922u8j0 , |
| beta-d-glucopyranosiduronic acid, (5alpha)-4,5-epoxy-14-hydroxy-6-oxo-17-(2-propenyl)morphinan-3-yl |
| naloxone 3-o-beta-d glucuronide |
| Q27269752 |
| (2s,3s,4s,5r,6s)-6-[[(4r,4as,7ar,12bs)-4a-hydroxy-7-oxo-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid |
| naloxone 3-?-d-glucuronide |
| naloxone-3-beta-d-glucuronide |
| naloxone-3-beta-d-glucuronide, 1mg/ml in methanol/water : 1/1 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|
| "The aim of this paper was to report the pharmacokinetic results from a single-dose study and a multiple-dose bioequivalence study of OXN versus separate formulations of oxycodone PR and naloxone PR administered concurrently in healthy subjects." | ( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008) | 0.35 |
| " The pharmacokinetic properties of the OXN FDC were similar to those of oxycodone PR + naloxone PR given as separate formulations, based on the regulatory definition." | ( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008) | 0.35 |
| "We analysed samples from three pharmacokinetic studies to determine the serum concentrations of naloxone-3-glucuronide (N3G), the main metabolite of naloxone, with or without exposure to remifentanil." | ( The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Dale, O; Skarra, S; Skulberg, AK; Tylleskar, I, 2021) | 0.84 |
| " The dose-corrected Cmax of N3G after intranasal administration of naloxone under remifentanil exposure was significantly lower (4." | ( The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Dale, O; Skarra, S; Skulberg, AK; Tylleskar, I, 2021) | 0.62 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|
| " Treatments were considered bioequivalent if the 90% CIs for relative bioavailability calculations fell within a predetermined range of 80% to 125%." | ( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008) | 0.35 |
| " These findings suggest that the coadministration of oxycodone PR and naloxone PR in an FDC would not significantly affect the bioavailability of either of its constituents in these subjects." | ( Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Bailey, P; Grothe, B; Hopp, M; Leyendecker, P; Mundin, G; Reimer, K; Smith, K; Uhl, R, 2008) | 0.35 |
| "Remifentanil has been shown to increase the bioavailability of nasally administered naloxone." | ( The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Dale, O; Skarra, S; Skulberg, AK; Tylleskar, I, 2021) | 0.62 |
| "Remifentanil increases the bioavailability of naloxone after nasal administration by reducing the pre-systemic metabolism of the swallowed part of the nasal dose." | ( The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers.
Dale, O; Skarra, S; Skulberg, AK; Tylleskar, I, 2021) | 0.62 |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 20.02 (24.57) | | Research Supply Index | 2.20 (2.92) | | Research Growth Index | 4.59 (4.65) | | Search Engine Demand Index | 15.26 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |